Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OVULEN 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OVULEN 21.
NORLESTRIN 28 1/50 vs OVULEN-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
None Documented
None Documented
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant.
Category C
Category C
Oral Contraceptive
Oral Contraceptive